No narrative about the commercialization efforts of regenerative medicine would be complete without the story of Tengion (TNGN). It represents a business school-caliber case study about the risks inherent in bringing a novel medical product to market, even with an impressive pedigree, best-in-class technology, a colossal market opportunity, financial support from seasoned institutional investors and experienced personnel. Through the second quarter of this year, TNGN boasts an accumulated deficit of ~$265M, no products even remotely close to gaining regulatory clearance anywhere in the world and IPO shares that have lost 99.9% of their value in only three and a half years. The educational value of TNGN's history to biotech investors is infinitely greater than any success story could ever hope...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|